Senolytic drug reduced bacterial burden in vitro model of chronic intracellular infection
An in vitro study examined how Mycobacterium abscessus infection induces senescence in alveolar macrophages through DNA damage signalling, which then spreads to neighboring cells via paracrine SASP secretion. Treatment with the senolytic drug Navitoclax selectively eliminated senescent cells and reduced bacterial burden to levels similar to antibiotic treatment.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 18, 2026 · Discovered: Sep 17, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- In vitro
- Sample size
- —
- Duration
- —
- Population
- Alveolar macrophages infected with Mycobacterium abscessus and neighboring uninfected cells
- Primary outcome
- Reduction in Mycobacterium abscessus bacterial burden following Navitoclax treatment
- Effect size
- —
- Significance
- Not reported
- Journal
- Nature Communications
- Published
- Aug 18, 2026
Sources
Primary source
- Nature communications ↗Peer reviewed
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.